Shattuck Labs Inc (STTK NASDAQ) stock market data APIs
$6.2476
0.33(5.3%)
as of May 15, 2026
Try our APIs with
free plan!
Shattuck Labs Inc Financial Data Overview
Price chart is built with
Anychart
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Prev. Close
6.2476
Open
6.5779
High
6.6548
Low
6.1838
52 wk Range
0.712-8.33
Market Cap
480 M
Shares Outstanding
76 681 K
Revenue
1 000 K
EPS
-0.13
Beta
1.186
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Shattuck Labs Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Shattuck Labs Inc data using free add-ons & libraries
Get Shattuck Labs Inc Fundamental Data
Shattuck Labs Inc Fundamental data includes:
- Net Revenue: 1 000 K
- EBITDA: -47 739 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-13
- EPS/Forecast: -0.1276
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Shattuck Labs Inc News
New
Cantor Fitzgerald Initiates Coverage of Shattuck Labs (STTK)
Shattuck Labs, Inc. (NASDAQ:STTK) is one of the best performing small cap stocks so far in 2026. Cantor Fitzgerald initiated coverage of Shattuck Labs, Inc. (NASDAQ:STTK) with an Overweight rating on...
Why Shattuck Labs Stock Soared More Than 53% Higher This Week
Key Points The biotech published its final earnings report and business covering 2025. It posted a slightly narrower-than-expected net loss for the fourth quarter.10 stocks we like better than Shattu...
Why Shattuck Labs Stock Soared More Than 53% Higher This Week
Shattuck Labs(NASDAQ: STTK) was an outlier in the healthcare sector this week, thanks mostly to a very well-received earnings report and business update. Over the five trading days, according to data ...
Shattuck Labs Posts Narrower FY25 Loss, Advances DR3 Antibody Pipeline
(RTTNews) - Shattuck Labs, Inc. (STTK) has reported fourth-quarter and full-year 2025 financial results and outlined progress across its pipeline targeting the TL1A/DR3 pathway, a central driver of im...
Get Shattuck Labs Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
